Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Aromatase Inhibitor (Letrozole) in Minimal Ovarian Stimulation Protocols in Assisted Reproductive Technology. A Randomized Controlled Trial

NCT02429999 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT02429999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Aromatase Inhibitor (Letrozole) in Minimal Ovarian Stimulation Protocols in Assisted Reproductive Technology. A Randomized Controlled Trial
Lead sponsor
Assiut University
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2015
Completion date
December 31, 2017
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

to evaluate letrozole as a modality for minimal ovarian stimulation in icsi cycles .